Post-translational Regulation Contributes to the Loss of LKB1 Expression Through SIRT1 Deacetylase in Osteosarcomas

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Jun 21

PMID 28632727

Citations 7

Authors

Nadege Presneau

Laure Alice Duhamel

Hongtao Ye

Roberto Tirabosco

Adrienne M Flanagan

Malihe Eskandarpour

Affiliations

Soon will be listed here.

Abstract

Background: The most prevalent form of bone cancer is osteosarcoma (OS), which is associated with poor prognosis in case of metastases formation. Mice harbouring liver kinase B1 (LKB1) develop osteoblastoma-like tumours. Therefore, we asked whether loss of LKB1 gene has a role in the pathogenesis of human OS.

Methods: Osteosarcomas (n=259) were screened for LKB1 and sirtuin 1 (SIRT1) protein expression using immunohistochemistry and western blot. Those cases were also screened for LKB1 genetic alterations by next-generation sequencing, Sanger sequencing, restriction fragment length polymorphism and fluorescence in situ hybridisation approaches. We studied LKB1 protein degradation through SIRT1 expression. MicroRNA expression investigations were also conducted to identify the microRNAs involved in the SIRT1/LKB1 pathway.

Results: Forty-one per cent (106 out of 259) OS had lost LKB1 protein expression with no evident genetic anomalies. We obtained evidence that SIRT1 impairs LKB1 protein stability, and that SIRT1 depletion leads to accumulation of LKB1 in OS cell lines resulting in growth arrest. Further investigations revealed the role of miR-204 in the regulation of SIRT1 expression, which impairs LKB1 stability.

Conclusions: We demonstrated the involvement of sequential regulation of miR-204/SIRT1/LKB1 in OS cases and showed a mechanism for the loss of expression of LKB1 tumour suppressor in this malignancy.

Citing Articles

The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma.

Xie Q, Zeng Y, Zhang X, Yu F Cancer Immunol Immunother. 2024; 73(9):171.

PMID: 38954021 PMC: 11220057. DOI: 10.1007/s00262-024-03748-9.

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.

Trelford C, Shepherd T Cell Commun Signal. 2024; 22(1):310.

PMID: 38844908 PMC: 11155146. DOI: 10.1186/s12964-024-01689-5.

Cathepsin K Non-Osteoclast Cells in the Skeletal System: Function, Models, Identity, and Therapeutic Implications.

Zou N, Liu R, Li C Front Cell Dev Biol. 2022; 10:818462.

PMID: 35912093 PMC: 9326176. DOI: 10.3389/fcell.2022.818462.

Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines.

Ayers J, Milner R, Cortes-Hinojosa G, Riva A, Bechtel S, Sahay B J Vet Diagn Invest. 2021; 33(2):261-278.

PMID: 33446089 PMC: 7944434. DOI: 10.1177/1040638720985242.

Beyond Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment.

Borzi C, Galli G, Ganzinelli M, Signorelli D, Vernieri C, Garassino M Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33202760 PMC: 7697441. DOI: 10.3390/ph13110385.

References

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

Li J, Liu J, Li P, Mao X, Li W, Yang J . Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. J Exp Clin Cancer Res. 2014; 33:70. PMC: 4431490. DOI: 10.1186/s13046-014-0070-0. View

Hori Y, Kuno A, Hosoda R, Horio Y . Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013; 8(9):e73875. PMC: 3770600. DOI: 10.1371/journal.pone.0073875. View

Bouras T, Fu M, Sauve A, Wang F, Quong A, Perkins N . SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem. 2005; 280(11):10264-76. DOI: 10.1074/jbc.M408748200. View

Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K . Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med. 2014; 3(4):980-7. PMC: 4303166. DOI: 10.1002/cam4.268. View

Partanen J, Tervonen T, Myllynen M, Lind E, Imai M, Katajisto P . Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc Natl Acad Sci U S A. 2012; 109(7):E388-97. PMC: 3289385. DOI: 10.1073/pnas.1120421109. View

Godlewski J, Nowicki M, Bronisz A, Nuovo G, Palatini J, De Lay M . MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010; 37(5):620-32. PMC: 3125113. DOI: 10.1016/j.molcel.2010.02.018. View

Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y . MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1. Oncol Rep. 2015; 34(1):399-406. DOI: 10.3892/or.2015.3986. View

Zu Y, Liu L, Lee M, Xu C, Liang Y, Man R . SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res. 2010; 106(8):1384-93. DOI: 10.1161/CIRCRESAHA.109.215483. View

10.

Deng C . SIRT1, is it a tumor promoter or tumor suppressor?. Int J Biol Sci. 2009; 5(2):147-52. PMC: 2631220. DOI: 10.7150/ijbs.5.147. View

11.

Ylikorkala A, Avizienyte E, Tomlinson I, Tiainen M, Roth S, Loukola A . Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet. 1999; 8(1):45-51. DOI: 10.1093/hmg/8.1.45. View

12.

Boardman L, Thibodeau S, Schaid D, Lindor N, McDonnell S, Burgart L . Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998; 128(11):896-9. DOI: 10.7326/0003-4819-128-11-199806010-00004. View

13.

Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J . miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res. 2014; 20(23):6187-99. DOI: 10.1158/1078-0432.CCR-14-1030. View

14.

Lizcano J, Goransson O, Toth R, Deak M, Morrice N, Boudeau J . LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004; 23(4):833-43. PMC: 381014. DOI: 10.1038/sj.emboj.7600110. View

15.

Shorning B, Clarke A . LKB1 loss of function studied in vivo. FEBS Lett. 2011; 585(7):958-66. DOI: 10.1016/j.febslet.2011.01.019. View

16.

Sobottka S, Haase M, Fitze G, Hahn M, Schackert H, Schackert G . Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol. 2001; 49(3):187-95. DOI: 10.1023/a:1006442024874. View

17.

Lao G, Liu P, Wu Q, Zhang W, Liu Y, Yang L . Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1. Tumour Biol. 2014; 35(12):11933-8. DOI: 10.1007/s13277-014-2479-7. View

18.

Kovac M, Blattmann C, Ribi S, Smida J, Mueller N, Engert F . Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015; 6:8940. PMC: 4686819. DOI: 10.1038/ncomms9940. View

19.

Bae H, Noh J, Kim J, Eun J, Jung K, Kim M . MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2013; 33(20):2557-67. DOI: 10.1038/onc.2013.216. View

20.

Bai B, Man A, Yang K, Guo Y, Xu C, Tse H . Endothelial SIRT1 prevents adverse arterial remodeling by facilitating HERC2-mediated degradation of acetylated LKB1. Oncotarget. 2016; 7(26):39065-39081. PMC: 5129914. DOI: 10.18632/oncotarget.9687. View